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ABSTRACT Mycosis fungoides is the most common primary cuta-
neous T cell lymphoma, characterized by erythematous patches 
and plaque lesions with slow progression to cutaneous tumors or 
extracutaneous involvements in some patients. We aimed to evalu-
ate the clinical characteristics, treatment responses, disease cours-
es, and mortality rates of our MF cases. The data of 100 patients 
with MF were retrospectively examined from medical records in our 
clinic between January 2005 and January 2015. Demographic and 
clinical characteristics of the patients, disease stage, treatment pro-
tocols, response to treatment, recurrence, progression, and mortal-
ity rates were recorded. The male to female ratio in patients was 
1.2. Mean age at onset of disease was 46, and duration of disease 
ranged from one to 42 years. At time of diagnosis 31 patients were 
at stage 1A, 31 at stage 1B, 30 at stage 2A, 2 at stage 2B, 1 at stage 
3, and 5 at stage 4. Stable disease was observed in 35% of patients, 
progression in 10%, relapse in 27%, and complete response in 28%. 
Large cell transformation was found in 3 patients and additional 
malignity in 11. Thirty-seven patients (37%) were still surviving dis-
ease-free. 10 patients had died, three of them due to disease-relat-
ed conditions. The most common first-line therapy in our study was 
phototherapy. It was applied to 87% of patients from stage 1A. Our 
results are generally consistent with current literature, but disease 
progression and disease-specific mortality rates were significantly 
lower than the literature, probably due to early phototherapy.
KEY WORDS: mycosis fungoides, disease progression, relapse,  
survival
INTRODUCTION
Cutaneous T cell lymphomas (CTCLs) are a hetero-
geneous group of non-Hodgkin lymphomas charac-
terized by clonal diffusion of neoplastic T-cells in the 
skin. The most common type is mycosis fungoides 
(MF), which constitutes approximately 50% of CTCLs 
(1). The global incidence of MF is 0.36-0.64/100,000, 
and mean age at time of diagnosis is 55-58 (1,2).
There is still no curative treatment for MF. There-
fore, the objective of treatment is to improve patients’ 
quality of life, to ameliorate symptoms by minimiz-
ing treatment toxicity, and to achieve and maintain 
remission (3). Patient characteristics, comorbidities, 
and prognostic markers are important in treatment 
selection (2).
In contrast to other lymphoproliferative diseases 
in which cytogenetic and laboratory findings play a 
decisive role, in MF TNMB (tumor, node, metastasis, 
and blood) staging is still an important prognostic 
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factor for selection of risk-based therapy (4,5). Most 
patients with MF are in the limited disease stage at di-
agnosis (6). Tumoral lesions (T3), erythroderma (T4), 
nodal involvement with partial or complete destruc-
tion (N3), organ metastasis (M1), or severe leukemic 
involvement (B2) are seen in advanced stages of the 
disease (4).
Skin-targeted therapies are the first choice for 
treatment in early stages. These treatments include 
topical corticosteroids, topical chemotherapy agents 
(nitrogen mustard, carmustine), topical retinoids, 
topical imiquimod, narrowband ultraviolet B (nbUVB), 
psoralen and ultraviolet A (PUVA), radiotherapy, and 
total skin electron irradiation. Systemic treatments 
include biological agents, immunomodulators, che-
motherapeutic agents, stem cell transplantation, and 
extracorporeal photopheresis (7).
The purpose of this study was to analyze the de-
mographic characteristics, treatment selection, re-
sponses, clinical course, and mortality rates in cases 
of MF from our center in northeastern Turkey.
PATIENTS AND METHODS
We retrospectively reviewed the data of patients 
who were diagnosed with MF at our Department of 
Dermatology, Trabzon, Turkey between January 2005 
and January 2015. 130 patients with histopathologi-
cal results and ICD codes compatible with MF were 
included in the study. However, non-MF CTCL was 
present in 15 of these patients. Another 15 patients 
were excluded from the study due to lack of clinical 
follow-up after diagnosis. Finally, 100 patients clini-
cally and histopathologically confirmed with MF were 
enrolled. Disease stages for all patients, agents used 
in treatment, responses to treatments, recurrence, 
progression, and mortality rates were recorded and 
correlations were evaluated. 
Patients were staged according to the EORTC. 
Course of disease was examined under four head-
ings – complete remission, stable disease, progres-
sion (advanced stage, excluding mortality) or relapse. 
Stable disease was defined as a lack of progression 
to the next clinical stage. Progression was defined 
with pathologic lymph nodes indicating advanced 
stage progression (≥2B). Lactate dehydrogenase 
(LDH) levels, total IgE levels, peripheral blood eo-
sinophil counts, and Sezary cells at time of diagnosis 
were recorded. Causes of death were confirmed from 
clinical records or by contacting relatives. Treatments 
received, doses, duration of treatment, doses, accom-
panying systemic comorbid conditions, malignancies, 
and superficial lymph node ultrasonography findings 
of the axillary and inguinal lymph nodes were evalu-
ated. In the presence of palpable lymphadenopathy, 
lymph node ultrasonography were carried out rou-
tinely in our clinic. Biopsy was performed if there was 
a pathologic lymph node on ultrasonography. For the 
evaluation of response to treatment, control biopsies 
and clinical examination records from patients were 
reviewed. 
The data were analyzed on SPSS (Statistical Pack-
ages for Social Analysis) version 13.0 software. Mea-
surements of data were expressed as mean ± stan-
dard deviation, and numerical data as number (%). 
The chi square test was applied to analyze relations 
between two variables.
RESULTS 
Patient data
Hundered cases diagnosed with MF between Jan-
uary 2005 and January 2015 were enrolled. The ratio 
of women to men was 0.85, and patient ages ranged 
between 16 and 95. Mean age at onset of disease was 
46, and mean time from onset of symptoms to diag-
nosis was 1.89±2.61 years. Duration of disease ranged 
between one to 42 years (mean 11.36±8.95). The 
mean follow-up period of the patients was 5.26±2.36 
years. Previous diagnosis of non-specific dermatitis 
was present in 6 patients, and previous history of 
parapsoriasis confirmed by biopsy was present in 10. 
Seven of the patients had parapsoriasis diagnosed as 
large plaque parapsoriasis based on the clinical fea-
tures of the lesion (Table 1).
Table 1. Demographics of 100 patients with mycosis fungoides 
Women/men (n) 46/54
Mean age ± SD (year) 46.29±16.54
Time to diagnosis ± SD (year) 1.89±2.61
Duration of disease (years) 1-42
Parapsoriasis (n) 10
Malignancy (n) 11
Large cell transformation (n) 3
Mortality (n) 10
*SD: Standard deviation
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Stage, progression, relapses 
Fifty-seven patients had patch lesions, 27 had 
plaques, 10 patients had tumoral lesions, and 6 pa-
tients were erythrodermic. Thirty-one patients (31%) 
were stage 1A at time of diagnosis, 31 (31%) were 
stage 1B, 30 (30%) were stage 2A, 2 (2%) were stage 
2B, 1 (1%) was stage 3, and 5 (5%) were stage 4. Stable 
disease was found in 35 patients, progression in 10, 
relapse in 27, and complete response in 28. In stage 
1A cases stable disease was found in eight, progres-
sion in one, complete response in 14 and relapse in 
eight. In stage 1B patients stable disease was found in 
12, progression in four, complete response in 7, and 
relapse in 8.  
Stable disease was found in 9 of the stage 2A 
cases, progression in 3, complete response in 6, and 
relapse in 12. Stable disease was found in one of the 
stage 2B cases and progression in the other. Stable 
disease was present in stage 3 patients. Stable dis-
ease was determined in 4 of the stage 4 cases and 
progression in 1.
The treatment protocols given according to the 
disease stage are summarized in Table 2.
Treatment
At early stages all patients received adjuvant topi-
cal corticosteroid therapy, clobetasol 0.05% being 
generally employed. Topical corticosteroids were 
generally combined with phototherapy. In stage 1A, 
topical imiquimod was applied to one patient with 
limited lesions not responding to topical cortico-
steroids, and retinoid acid was applied to another. 
However, the treatments could not be tolerated due 
to irritation. Local radiotherapy was applied to early 
stage patients with limited resistant lesions. We used 
electron beam therapy with a usual total dose of 20 
to 24 Gy administered in 10 to 12 fractions. Subtotal 
or total improvement was observed in all patients 
receiving radiotherapy. Phototherapy was applied 
to 87% of patients (PUVA to 33 and nbUVB to 54) as 
the first-line treatment option. Both phototherapy 
options were applied three times weekly. Complete 
response was observed in 51% of subjects receiving 
PUVA and in 56% of those receiving nbUVB. The mean 
relapse duration after treatment was 11.52 months. 
The response to treatment with nbUVB rates were 
high, particularly in patients with patch lesions, but 
relapse rates were also common. PUVA therapy was 
preferred in patients (33%) with thicker plaques and 
tumoral lesions and when no response was achieved 
with narrowband UVB therapy. Relapse was deter-
mined in 10 (19%) of the patients receiving narrow-
band UVB therapy and in 7 (21%) of those receiving 
PUVA therapy. We generally used maintenance treat-
ment, especially in patients with frequent relapses, 
generalized disease (≥1B), and advanced stages. 
Once clearance of lesions has been achieved photo-
therapy with three time a week (30-40 sessions), we 
then applied maintenance treatment in the form of 
6 sessions twice a week, 6 sessions once a week, and 
then 4 sessions in 2 weeks.
Twenty percent of patients received systemic 
therapy or chemotherapy. The most commonly em-
ployed systemic agents were interferon, bexarotene, 
and acitretin. These agents were generally adminis-
tered concurrently with phototherapy. Bexarotene 
Table 2. Therapeutic approaches based on the of clinical stage of the disease
Stage 1A Stage 1B Stage 2A Stage 2B Stage 3 Stage 4
Topical steroids* 100.0%* 100.0%* 100.0%* - - -
Phototheraphy alone 90.4% 84.5% 77.1% - - -
Phototheraphy and interferon - 6.2% 14.2% 67,8% - 17.0%
Phototheraphy and retinoids - - 5.7% 16,6% - -
Topical imiquimod 3.2% 6.2%* - - - -
Topical retinoid 3.2% 3.1%* 2.8%* - - -
Interferon - - - - -
Bexarotene - - - 16,6% - -
Acitretin - - - - - -
Local radiotherapy 3.2% - - - - -
Total skin electron beam therapy - - - - - -
Extracorporeal photopheresis - - - - 100.0% -
Monochemotherapy - - - - - -
Polichemotherapya - - - - - 83.0%
*Adjuvant therapy
aCHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)
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therapy was administered to 6 patients at a mean dai-
ly dosage of 300 mg/m2 and was combined with nbU-
VB in 4 cases. The drug was discontinued due to lipid 
elevation in 2 patients and central hypothyroidism in 
another one. Disease control was achieved in 3 other 
patients, but could not be maintained due to lipid 
elevation in one patient, while treatment response 
was achieved in another but tumoral lesions subse-
quently developed. Interferon alpha therapy was ad-
ministered to 13 patients and was used in combina-
tion with phototherapy. Acitretin and nbUVB therapy 
were applied to one patient. Stabilization of disease 
was achieved under treatment, but the lesions then 
increased after the first year of therapy.
CHOP protocol (cyclophosphamide, doxorubicin, 
vincristine, and prednisone) was applied in 4 cases of 
stage 4. 
LDH elevation was present in 10 (10%) patients, eo-
sinophilia in peripheral blood in 12 (12%), and total IgE 
elevation in 13 (13%). Sezary cells were found in periph-
eral smears in 2 patients. Large cell transformation was 
observed in three patients and additional malignancy 
in 11 patients. Hodgkin lymphoma was found in 2 of 
these patients, non-Hodgkin lymphoma in 1, invasive 
ductal carcinoma of the breast in 2, thyroid papillary 
carcinoma in 2, lung cancer in 2, colon cancer in 1, and 
hepatocellular carcinoma in 1. Thirty-seven patients 
were still surviving disease-free at the end of follow-up, 
while 10 had died, 3 of them due to the disease.
DISCUSSION
We evaluated the clinical characteristics and dis-
ease course of patients with MF in Turkey. Several 
mostly retrospective studies have been published on 
demographics and disease course of MF and Sezary 
syndrome (Table 3). In the literature the mean age at 
onset of the disease ranges between 54 and 64 (2,6). 
The mean age at onset in the present study and the 
other study from Turkey was 46 (8). Compared with 
other countries, we can conclude that Turkish patients 
had a younger age presentation. We think that patients 
are diagnosed at early stages of the disease due to ear-
ly admission to dermatology clinics. The disease has 
been reported as more common in men in literature, 
which is in accordance with our study (1.2/1) (9,10).
MF is known as a slow progressive disease, and 
no decrease in the life span of stage 1A patients has 
been reported in most studies (2). In a multicenter 
retrospective study Quaglino et al. followed 1422 
patients with MF and SS for an average of 14.5 years 
from diagnosis and reported that the majority of pa-
tients were in the early stage of the disease at time 
of diagnosis (stages 1A-2A, 87%). In the same study 
the risk of progression was shown to increase in more 
advanced stages. Progression levels in stage 1A, 1B, 
and ≥2A were 25%, 29%, and 40%, respectively. In 
the same study, 5-10 years life expectancy has also 
been shown to be decreased as the stage of disease 
increased (11). In a cohort study with 1502 patients, 
Agar et al. reported progression in 34% of subjects 
during follow-up and that 24% of patients died due 
to the disease (6). Ninety-two of the patients in our 
study had early-stage MF at the time of diagnosis. 
Disease progression regardless of stage was 10% in 
our study and the disease-specific mortality rates 
were 3%. Disease progression rates in the literature 
were reported between 10-34% (2,8,10-12). Death 
due to disease related conditions was considered as 
disease progression in Talpur et al. (10) and Agar et 
al. (6), but in our study and other abovementioned 
studies death due to disease was not classified as pro-
gression. In our study and the study by Anadolu et al. 
(8) from Turkey, disease progression was significantly 
lower. We may explain this by earlier diagnosis and 
treatment initiation in the Turkish population or due 
to do early treatment with phototherapy.
Table 3. Demographic characteristics and progression and mortality rates of mycosis fungoides in different 
       countries
Authors Country Patient (n) Sex 
(M:F)
Mean age (years) Progression
(%)
Mortality
(%)
Agar . (6) UK 1502 1.64 54.0 34.0 26.0
Talpur et al. (10) USA 1263 1.11 55.3 28.5 8.1
Desai et al. (12)* USA (Georgia) 393 1.11 53.6 21.9 19.6
Eklund et al. (2)* Sweden 44 1.60 64.0 25.0 25.0
Doorn et al. (21)* Netherland 309 1.73 61.0 25.0 15.0
Quaglino et al. (11)* Italy 1422 1.72 59.0 29.7 -
Anadolu RY et al. (8) Turkey 113 0.94 46.0 10.0 6.0
Baykal Selcuk et al.* Turkey 100 1.20 46.0 10.0 3.0
F: Female; M: Male 
**Studies including only patients with mycosis fungoides
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Cohort studies have shown an increased risk of 
a second primary lymphoma developing in patients 
with MF and SS, particularly Hodgkin lymphoma. In 
a retrospective analysis of the two cohort studies in 
the literature, the development of additional solid 
organ cancer rates was 8.9% and 11% (13). This rate 
was 11% in our study. Hodgkin lymphoma was found 
in 2 patients, non-Hodgkin lymphoma in 1, invasive 
ductal carcinoma of the breast in 2, thyroid papillary 
carcinoma in 2, lung cancer in 2, colon cancer in 1, 
and hepatocellular carcinoma in 1. Olsen et al. found 
an increase in secondary cancer development in pa-
tients with MF, but in contrast to other cohort stud-
ies they also included cancer cases diagnosed before 
MF diagnosis as secondary cancer (14). The reason for 
the increased risk of a second malignant neoplasm in 
patients with MF and SS is unknown. However, these 
secondary cancers are probably associated with the 
treatments of the disease. Alternatively, MF may have 
a common underlying environmental factor or a na-
tive tendency for the development of certain malig-
nant neoplasms (13,15).
Large cell transformation in MF, diagnosed when 
large cells exceed 25% of the total lymphocyte count, 
is approximately 10-25%, depending on the stage 
(16). A retrospective analysis of 297 patients reported 
a level of large cell transformation of 1.4% in stage 1A 
and 2A disease, but 67% in 4B disease (17). Transfor-
mation was observed in 3 patients in our study. We 
attribute the lower rates in our research compared 
WITH the literature to the low number of advanced 
stage patients. 
Phototherapy is a safe, effective, and well tolerated 
first-line treatment in patients with early stage of MF 
(1A-2A). Although the evidence for the effectiveness 
of narrowband UVB therapy is lower, it is thought to 
be as effective as PUVA in the initial treatment of ear-
ly stage MF. It is preferred in patients with patch and 
thin lesions. PUVA therapy may be reserved for thick 
plaques and patients resistant to narrowband UVB 
therapy. It is recommended that PUVA or narrowband 
UVB treatment be administered three times per week 
until the lesions fully clear (18). Once remission has 
been achieved, there is no consensus regarding main-
tenance treatment. Avoiding maintenance therapy is 
recommended in the recently published EORTC (18). 
Sanchez et al. showed that maintenance therapy with 
PUVA did not prevent relapse in follow-up over ap-
proximately 28 months (19). Pavlotsky et al. reported 
that maintenance treatment in broadband and nar-
rowband UVB therapy did not reduce relapse rates in 
cutaneous T-cell lymphoma (20). In the literature, the 
use of phototherapy in treatment of mycosis fungoi-
des is significantly lower compared with our study. 
Quaglino et al. used phototherapy alone or with 
systemic agents in 54% of patients in stage 1, 31% 
in stage 2, 14% in stage 3, and 2.6% in stage 4 (11). 
Eklund et al. treated 70% of the patients with photo-
therapy as a first-line agent. They used PUVA twice a 
week for a total of 24-30 times: narrowband UVB was 
administered three times weekly with a similar num-
ber of treatments (2). Doorn et al. used phototherapy 
in 71% of the patients in stage 1 and 39% in stage 
2 (21). Anadolu et al. used phototherapy in 91% of 
patients in early stages (<2B) and 33% in late stages 
(≥2B) (8). Phototherapy protocols were administered 
three times weekly, and mean duration of therapy 
was 21.50 months in early stages and 17.25 months in 
late stages. We used phototherapy alone or with sys-
temic agents in 90% of stage 1A patients, 91% stage 
1B, 97% stage 2A, and 100% stage 2B patients. We 
used maintenance treatment especially in patients 
with frequent relapses, generalized disease (≥1B) and 
advanced stages. We think that maintenance therapy 
could prevent progression of the disease. We had low 
progression rates despite the literature, which we can 
explain by early administration of phototherapy and 
maintenance therapy in the phototherapy protocol.  
Our research was performed as a retrospective 
and single-center study. It also has various limita-
tions, such as a low number of cases.  
CONCLUSION
MF is a chronic disease with frequent relapses and 
disease progression despite treatments. Our study is 
a report from Turkey on demographic data and over-
all outcome of patients with MF. As expected, signifi-
cant rates of stable disease and relapses were found 
in our patients. Unlike in the literature, mortality rates 
and disease progression were significantly lower. This 
chronic course of the disease and frequent relapses 
require new treatment regimens to achieve complete 
remission in patients. We observed an increased addi-
tional malignancy in our study. Further multi-center 
and prospective studies assessing prognostic factors, 
mortality rates, and responses to treatment in cases 
of MF in Turkey are needed.
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